With the recent sell-off in biotech stocks, the author of today’s article advises that “this is the perfect opportunity to buy into high-growth biotech stocks at a reduced price. It’s just a matter of finding the right company within one of the hottest – yet unknown – sectors of the market.” He proceeds to highlight one company that appears to fit the bill – a very small firm on the front lines of developing therapeutics for potential biological weapons attacks. For more on this stock – which is expected to outperform the broader market by three times in the next 12 months – CLICK HERE.
This High-Growth Small Cap Is On The Front Lines Of Developing Therapies For Potential Bio Attacks – And It’s Trading At A Discount
- by RobH